Company profile
Beijing Immunochina Medical Science & Technology Co., Ltd.
Privately held: no public share price (Privately-held Chinese CAR-T biopharma (also known as Yimiao Shenzhou), founded 2015, raised a $20M Series C; confirmed private (Fierce Biotech, Dealroom). Sources: https://clinicaltrials.gov/study/NCT04537442 Entity resolved by asset-pipeline-v2.)
Assets
(4 total)
4Total Assets
0Approved
1Phase 3 / Filed
3Phase 1–2 / Early
3Diseases
Quick filter:
| Target & Modality | |||
|---|---|---|---|
| Phase 3 | CD44v9Antibody–drug conjugate | Non-Small Cell Lung Cancer | |
| Phase 1 | CD19 | Systemic Lupus Erythematosus | |
IM21 CAR-T cellsNo recent activity | Phase 1 | BCMACell therapy | Multiple Myeloma |
| Phase 1 | CD19 | Systemic Lupus Erythematosus |
Upcoming events
Research
Sign in to access ResearchUnlock the company readout calendar
Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.
Financial reports
Research
Sign in to access ResearchUnlock sourced financial history
Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.